Literature DB >> 26815505

Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma.

Xiaoying He1, Yun Liao2, Wen Lu3, Gufeng Xu2, Huan Tong4, Jieqi Ke4, Xiaoping Wan5.   

Abstract

Overexpression of stathmin (STMN1) is closely linked to tumor metastases and poor prognosis in endometrial carcinoma (EC). However, the underlying mechanism is little known. In the present study, we investigated the expression of STMN1 in EC. Subsequently, we assessed the role of STMN1 in EC cell proliferation and migration. Our data show that STMN1 is upregulated in EC, and elevated expression of STMN1 is correlated positively with tumor stage and lymph node metastasis. In vitro, forced expression of STMN1 promoted cell invasion and migration. In contrast, knockdown of STMN1 inhibited cell aggressive behaviors. Moreover, the expression and the activity changes of matrix metalloproteinases (MMP)-2/9 were observed in EC cells after the cells being silenced or overexpression of STMN1. In conclusion, STMN1 is an oncogene and it enhances the growth and invasion of EC possibly by mediating the secretion and activation of MMP2 and MMP9 protein.

Entities:  

Keywords:  Endometrial cancer; Gelatin zymography; MMP2; MMP9; STMN1

Mesh：

Substances：

Year:  2016        PMID： 26815505     DOI： 10.1007/s13277-016-4869-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  22 in total

1.  PAK4 is activated via PI3K in HGF-stimulated epithelial cells.

Authors:  Claire M Wells; Arie Abo; Anne J Ridley
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

2.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

3.  Stathmin is a potential molecular marker and target for the treatment of gastric cancer.

Authors:  Xiaolin Liu; Hairong Liu; Jing Liang; Beibei Yin; Junjuan Xiao; Junwei Li; Dongfeng Feng; Yan Li
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma.

Authors:  M Iurlaro; G Loverro; A Vacca; G Cormio; D Ribatti; M Minischetti; R Ria; M Bruno; L Selvaggi
Journal:  Eur J Clin Invest       Date:  1999-09       Impact factor: 4.686

5.  High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Authors:  Elisabeth Wik; Even Birkeland; Jone Trovik; Henrica M J Werner; Erling A Hoivik; Siv Mjos; Camilla Krakstad; Kanthida Kusonmano; Karen Mauland; Ingunn M Stefansson; Frederik Holst; Kjell Petersen; Anne M Oyan; Ronald Simon; Karl H Kalland; William Ricketts; Lars A Akslen; Helga B Salvesen
Journal:  Clin Cancer Res       Date:  2013-03-28       Impact factor: 12.531

6.  Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.

Authors:  Raghavan Balachandran; Manda J Welsh; Billy W Day
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

7.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Authors:  H B Salvesen; S L Carter; M Mannelqvist; A Dutt; G Getz; I M Stefansson; M B Raeder; M L Sos; I B Engelsen; J Trovik; E Wik; H Greulich; T H Bø; I Jonassen; R K Thomas; T Zander; L A Garraway; A M Oyan; W R Sellers; K H Kalland; M Meyerson; L A Akslen; R Beroukhim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

Review 8.  Stathmin 1: a novel therapeutic target for anticancer activity.

Authors:  Shushan Rana; Phillip B Maples; Neil Senzer; John Nemunaitis
Journal:  Expert Rev Anticancer Ther       Date:  2008-09       Impact factor: 4.512

9.  PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.

Authors:  Xueqiong Fu; Jiarui Feng; Duan Zeng; Yu Ding; Changshou Yu; Bing Yang
Journal:  Biosci Rep       Date:  2014-04-01       Impact factor: 3.840

10.  Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients.

Authors:  Xia-Ying Kuang; Li Chen; Zhi-Jie Zhang; Yi-Rong Liu; Yi-Zi Zheng; Hong Ling; Feng Qiao; Shan Li; Xin Hu; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2015-09-08
View more
  11 in total

1.  High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Authors:  Henry D Reyes; Jeffrey Miecznikowski; Jesus Gonzalez-Bosquet; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Jean-Marie Stephan; Parviz Hanjani; Saketh Guntupalli; Krishnansu S Tewari; Floor Backes; Nilsa Ramirez; Gini F Fleming; Virginia Filiaci; Michael J Birrer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2017-05-19       Impact factor: 5.482

2.  miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer.

Authors:  Feng Guo; Yang Luo; Yi-Fei Mu; Shao-Lan Qin; Yang Qi; Yi-Er Qiu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  LncRNA LINC01116 Promotes the Development of Colorectal Cancer by Targeting miR-9-5p/STMN1.

Authors:  Chongyao Bi; Hongshuai Cui; Haijing Fan; Lai Li
Journal:  Onco Targets Ther       Date:  2020-10-15       Impact factor: 4.147

4.  Zyxin (ZYX) promotes invasion and acts as a biomarker for aggressive phenotypes of human glioblastoma multiforme.

Authors:  Xian-Mei Wen; Tao Luo; Yi Jiang; Li-Hong Wang; Ying Luo; Qian Chen; Kaidi Yang; Ye Yuan; Chunhua Luo; Xiang Zhang; Ze-Xuan Yan; Wen-Juan Fu; Yu-Huan Tan; Qin Niu; Jing-Fang Xiao; Lu Chen; Jiao Wang; Jia-Feng Huang; You-Hong Cui; Xia Zhang; Yan Wang; Xiu-Wu Bian
Journal:  Lab Invest       Date:  2020-01-16       Impact factor: 5.662

5.  Stathmin1 overexpression in hypopharyngeal squamous cell carcinoma: A new promoter in FaDu cell proliferation and migration.

Authors:  Yan Chen; Qicheng Zhang; Chuanjin Ding; Xiaobo Zhang; Xiaoxia Qiu; Zhenxin Zhang
Journal:  Int J Oncol       Date:  2016-11-23       Impact factor: 5.650

6.  Proteomic Signatures of Thymomas.

Authors:  Linan Wang; Owen E Branson; Konstantin Shilo; Charles L Hitchcock; Michael A Freitas
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

Review 7.  Overexpression of stathmin promotes metastasis and growth of malignant solid tumors: a systemic review and meta-analysis.

Authors:  Rong Biaoxue; Liu Hua; Gao Wenlong; Yang Shuanying
Journal:  Oncotarget       Date:  2016-11-29

Review 8.  Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Yang Shuanying
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531

9.  Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1.

Authors:  Juan Zhang; Jun Fu; Yuliang Pan; Xi Zhang; Liangfang Shen
Journal:  Onco Targets Ther       Date:  2016-12-01       Impact factor: 4.147

10.  Characterization of Lgr5+ Progenitor Cell Transcriptomes after Neomycin Injury in the Neonatal Mouse Cochlea.

Authors:  Shasha Zhang; Yuan Zhang; Pengfei Yu; Yao Hu; Han Zhou; Lingna Guo; Xiaochen Xu; Xiaocheng Zhu; Muhammad Waqas; Jieyu Qi; Xiaoli Zhang; Yan Liu; Fangyi Chen; Mingliang Tang; Xiaoyun Qian; Haibo Shi; Xia Gao; Renjie Chai
Journal:  Front Mol Neurosci       Date:  2017-07-04       Impact factor: 5.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.